Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tenalisib (RP6530)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Curon Biopharma, Rhizen

Drug class:

PI3K inhibitor, PI3Kδ inhibitor, PI3Kγ inhibitor, SIK3 inhibitor

Related drugs:

‹

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

enzastaurin (3)

BAY 1082439 (1)

copanlisib (32)

idelalisib (29)

linperlisib (1)

›

No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3	RP6530 Sensitive: C3 – Early Trials RP6530 Sensitive : C3